Routinely screened antibody fragments usually require further in vitro maturation to achieve
the desired biophysical properties. Blind in vitro strategies can produce improved ligands by …

Snakebite envenoming continues to claim many lives across the globe, necessitating the
development of improved therapies. To this end, broadly-neutralizing human monoclonal …

Snakebite envenoming (SBE), a neglected tropical disease, claims lives of about 138,000
people globally, and antivenom is the only approved treatment worldwide. However, this …

Improved therapies are needed against snakebite envenoming, which kills and permanently
disables thousands of people each year. Recently developed neutralizing monoclonal …

Recombinantly produced biotherapeutics hold promise for improving the current standard of
care for snakebite envenoming over conventional serotherapy. Nanobodies have performed …

Snakebite envenoming is a significant global health challenge, and for over a century,
traditional plasma-derived antivenoms from hyperimmunized animals have been the primary …

Snakebite envenoming is a neglected tropical disease that causes over 100,000 deaths
annually. Envenomings result in variable pathologies, but systemic neurotoxicity is among …

Phage display technology is a powerful tool for selecting monoclonal antibodies against a
diverse set of antigens. Within toxinology, however, it remains challenging to generate …

Snakebite envenomings kill~ 100 000 victims each year and leave many more with
permanent sequelae. Antivenoms have been available for more than 125 years but are in …

Immunoglobulin G (IgG) antibodies that bind their cognate antigen in a pH-dependent
manner (acid-switched antibodies) can release their bound antigen for degradation in the …